The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral ...

Medication nonadherence remains one of the widest gaps between how a drug performs in clinical trials and how it performs in ...

PharmTech covered one of the industry’s biggest events this week, as CPHI Milan was in full force with experts arguing that ...

Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use ...

Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere. Richard Jaenisch and Chris Cole dig into whether New Approach ...

Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be ...

Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs ...

As publishers and research platforms such as Reaxys and Springer Nature build application programming interface (API) access ...

Access Part 1 of this interview in which Scarboro explains why real-world usability belongs at product definition. Access ...

The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a ...

Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...

Manufacturers are encouraged to treat resiliency policy as an actionable trend and proactively shape solutions rather than ...